Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trial

The primary objective is to determine whether clopidogrel 75 mg/day by mouth, after a loading dose of 600 mg, is effective in preventing major ischemic vascular events (ischemic stroke, myocardial infarction, and ischemic vascular death) at 90 days when initiated within 12 hours of TIA or minor ischemic stroke onset in patients already receiving aspirin 50-325 mg/day (with a dose of 150-200 mg daily for 5 days followed by 75-100 mg daily strongly recommended).

Key Eligibilities:
-Minor ischemic stroke or high risk TIA. An ischemic stroke is a cerebral infarction. A transient ischemic attack (TIA) is a transient episode of neurological dysfunction caused by focal brain, spinal cord, or retinal ischemia, without acute infarction. Patients with TIA symptoms limited to isolated numbness, isolated visual changes, or isolated dizziness/vertigo are not eligible.
-Ability to randomize within 12 hours of time last known free of new ischemic symptoms.
-Head CT or MRI ruling out hemorrhage or other pathology.

Exclusion Criteria:
-Candidates for thrombolysis, endarterectomy or endovascular intervention, in the judgment of a treating physician, unless the subject declines both.
-Anticipated requirement for long-term (>7 day) non-study antiplatelet drugs, or Non-steroidal Anti-inflammatory Drugs (NSAIDs) affecting platelet function (such as prior vascular stent or arthritis).

**Other protocol-defined inclusion/exclusion criteria may apply. Please click on the NCT Number (below) to learn more about the study at**
Phase III
Amit Kansara, M.D.
Alexis Young
  • Providence Portland Medical Center
  • Providence St. Vincent Medical Center